Katherine Wesseling-Perry

Author PubWeight™ 16.08^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active.	J Clin Endocrinol Metab	2009	2.12
2	Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease.	Bone	2009	2.00
3	Value of the new bone classification system in pediatric renal osteodystrophy.	Clin J Am Soc Nephrol	2010	1.75
4	Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes.	J Bone Miner Res	2013	1.17
5	Disordered FGF23 and mineral metabolism in children with CKD.	Clin J Am Soc Nephrol	2013	1.05
6	Suppression of iron-regulatory hepcidin by vitamin D.	J Am Soc Nephrol	2013	1.03
7	The consequences of chronic kidney disease on bone metabolism and growth in children.	Nephrol Dial Transplant	2012	1.02
8	Short sleep duration is associated with higher energy intake and expenditure among African-American and non-Hispanic white adults.	J Nutr	2014	0.90
9	Racial differences in correlations between reported dietary intakes of carotenoids and their concentration biomarkers.	Am J Clin Nutr	2011	0.89
10	Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysis.	Nephrol Dial Transplant	2013	0.83
11	Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function.	Pediatr Nephrol	2012	0.82
12	The skeletal consequences of growth hormone therapy in dialyzed children: a randomized trial.	Clin J Am Soc Nephrol	2013	0.82
13	The role of bone in CKD-mediated mineral and vascular disease.	Pediatr Nephrol	2014	0.78
14	Cortical and trabecular bone in pediatric end-stage kidney disease.	Pediatr Nephrol	2014	0.75
15	Correction: Bone Canopies in Pediatric Renal Osteodystrophy.	PLoS One	2016	0.75